Ranbaxy’s Path Cleared For Authorized Prilosec Launch
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The 1.5 billion dollar Indian drug-maker Ranbaxy launched an authorized generic version of anti-ulcer drug omeprazole 40 mg in the U.S. as part of an agreement reached earlier with the gastric ulcer and Zollinger-Ellison syndrome treatment's innovator AstraZeneca